Active Systemic Lupus Erythematosus Clinical Trial
Official title:
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.
This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled extension study to characterising the long term safety and tolerability of of an intravenous treatment regimen of anifrolumab versus placebo in subjects with moderately to severely active systemic lupus erythematosus who completed a Phase 3 study (D3461C00004 or D3461C00005) through the 52-week double-blind treatment period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04931563 -
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
| Terminated |
NCT04680637 -
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT02446912 -
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
|
Phase 3 | |
| Completed |
NCT02446899 -
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
|
Phase 3 |